The Fertility Show, London, 1-3 November 2019
Page URL: https://www.bionews.org.uk/page_144987

HFEA urges IVF clinics to be more transparent about add-ons

16 September 2019
Appeared in BioNews 1015

The UK fertility regulator, the HFEA, has called for reforms in the way fertility add-on treatments are offered to patients, according to a consensus statement.

IVF clinics in the UK have come under further scrutiny by the HFEA after concerns that a high number of add-on IVF treatments continue to be offered to patients despite no conclusive evidence that they increase the chance of a pregnancy or live birth. Add-on treatments, such as endometrial scratching and assisted egg hatching, are not backed by strong clinical evidence, yet patient demand for these services remains high and so do the costs of treatment. 

Sally Cheshire, chair of HFEA, commented: 'We welcome the introduction of new treatments that could increase the chances of success; however, we want to see responsible innovation. Fertility treatment add-ons are being offered to more patients by clinics and we know many patients are asking for these add-ons and paying for them if they have private treatment.'

The HFEA and ten leading professional and patient fertility groups have published a consensus statement that aims to guide professionals and create a 'cultural change'. The recommendations to clinics include: only offering add-on treatments where more than one high-quality study demonstrates its safety and effectiveness, stopping treatment if concerns are raised regarding safety or effectiveness, informing patients of the experimental nature of add-ons where robust evidence is lacking and not charging patients extra to take part in a clinical trial.

Jason Kasraie, chair of the Association of Clinical Embryologists, said: 'We support greater transparency in the sector with regard to treatment add-ons. Whilst it is important that we work to ensure patients always receive the latest treatments and have access to new technologies in order to maximise their chance of treatment success, it is also essential that we ensure patients are fully informed and that only procedures or technologies that are evidence based are used.'

Earlier this year, the HFEA published a traffic light rating system to help patients identify if a particular add-on treatment is effective and safe for use (see BioNews 983). Despite the warnings from the first report demonstrating the lack of clinical evidence of add-on treatments, it is hoped that the latest consensus statement will ensure that clinics are transparent about add-ons and patients are well informed of their treatment choices.

Cheshire added: 'It's crucial that patients inform themselves about the add-ons they may be offered, so that they can ask the right questions, and make the right choices, when choosing what treatment to have. We've produced "traffic light" rated information on our website that keeps them up-to-date with the latest evidence on each of the most commonly offered add-ons.'

SOURCES & REFERENCES
Fertility regulator calls for clinics to be more open about treatment add-ons
HFEA |  12 September 2019
IVF clinics face new crackdown on add-on treatments
The Guardian |  10 September 2019
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
7 October 2019 - by Laura Riggall 
A new report from the Human Fertilisation and Embryology Authority (HFEA) has shown that fertility treatment is becoming safer, with the standard of care improving across UK clinics...
8 July 2019 - by Rikita Patel 
Wellness company Get A Drip has taken its 'fertility IV' drip off the market after the British Pregnancy Advisory Service (BPAS) said there was no evidence its treatment could improve fertility...
8 July 2019 - by Sally Cheshire 
Rarely a day goes by without the UK media mentioning assisted reproduction and the fertility sector. Whether it's the latest research innovation, the growth in DNA testing and matching websites, the funding and commissioning of fertility services or reports of patients confused as to whether they should pay for expensive and unproven add-on treatments...
4 February 2019 - by Dr Kamal Ahuja and Professor Nick Macklon 
Recently, the HFEA released a statement on adjunct treatments in IVF. The regulator had provided clear notice of its publication and both its stated intentions and content were as anticipated...
21 January 2019 - by Rikita Patel 
The Human Fertilisation and Embryology Authority has published a final consensus statement advising that IVF clinics should not charge patients for add-on treatments that are not proven effective by clinical trials...
17 December 2018 - by Ewa Zotow 
Sixty-two percent of private IVF patients paid 'more than they expected' for treatment, according to the first national patient survey by the HFEA.
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.